The pseudokinase NRBP1 activates Rac1/Cdc42 via P-Rex1 to drive oncogenic signalling in triple-negative breast cancer

被引:0
作者
Xue Yang
Miguel I. Cruz
Elizabeth V. Nguyen
Cheng Huang
Ralf B. Schittenhelm
Jennii Luu
Karla J. Cowley
Sung-Young Shin
Lan K. Nguyen
Terry C. C. Lim Kam Sian
Kimberley C. Clark
Kaylene J. Simpson
Xiuquan Ma
Roger J. Daly
机构
[1] Monash University,Cancer Program, Biomedicine Discovery Institute
[2] Monash University,Department of Biochemistry and Molecular Biology
[3] Monash University,Monash Proteomics and Metabolomics Facility
[4] Peter MacCallum Cancer Centre,Victorian Centre for Functional Genomics
[5] University of Melbourne,Sir Peter MacCallum Department of Oncology
来源
Oncogene | 2023年 / 42卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
We have determined that expression of the pseudokinase NRBP1 positively associates with poor prognosis in triple negative breast cancer (TNBC) and is required for efficient migration, invasion and proliferation of TNBC cells in culture as well as growth of TNBC orthotopic xenografts and experimental metastasis. Application of BioID/MS profiling identified P-Rex1, a known guanine nucleotide exchange factor for Rac1, as a NRBP1 binding partner. Importantly, NRBP1 overexpression enhanced levels of GTP-bound Rac1 and Cdc42 in a P-Rex1-dependent manner, while NRBP1 knockdown reduced their activation. In addition, NRBP1 associated with P-Rex1, Rac1 and Cdc42, suggesting a scaffolding function for this pseudokinase. NRBP1-mediated promotion of cell migration and invasion was P-Rex1-dependent, while constitutively-active Rac1 rescued the effect of NRBP1 knockdown on cell proliferation and invasion. Generation of reactive oxygen species via a NRBP1/P-Rex1 pathway was implicated in these oncogenic roles of NRBP1. Overall, these findings define a new function for NRBP1 and a novel oncogenic signalling pathway in TNBC that may be amenable to therapeutic intervention.
引用
收藏
页码:833 / 847
页数:14
相关论文
共 241 条
[1]  
Garrido-Castro AC(2019)Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment Cancer Discov 9 176-98
[2]  
Lin NU(2020)Personalized treatment in metastatic triple‐negative breast cancer: The outlook in 2020 Breast J 26 69-80
[3]  
Polyak K(2006)Emerging roles of pseudokinases Trends cell Biol 16 443-52
[4]  
Azim HA(2010)Pseudokinases-remnants of evolution or key allosteric regulators? Curr Opin Struct Biol 20 772-81
[5]  
Ghosn M(2014)Day of the dead: pseudokinases and pseudophosphatases in physiology and disease Trends cell Biol 24 489-505
[6]  
Oualla K(2013)Nuclear receptor-binding protein 1: a novel tumour suppressor and pseudokinase Biochem Soc Trans 41 1055-60
[7]  
Kassem L(2012)Nuclear receptor binding protein 1 regulates intestinal progenitor cell homeostasis and tumour formation EMBO J 31 2486-97
[8]  
Boudeau J(2020)NRBP1-containing CRL2/CRL4A regulates Amyloid β production by targeting BRI2 and BRI3 for degradation Cell Rep 30 3478-91.e6
[9]  
Miranda-Saavedra D(2002)MADM, a novel adaptor protein that mediates phosphorylation of the 14-3-3 binding site of myeloid leukemia factor 1 J Biol Chem 277 40997-1008
[10]  
Barton GJ(2002)Interaction of the small GTPase Rac3 with NRBP, a protein with a kinase-homology domain Int J Mol Med 9 451-9